All
What are you thankful for this year?
November 14th 2017It's that time of year when we sit back and reflect on where we are and where we've come. When you look around you at the office or at home, what are the things and who are the people that you truly appreciate? Here at Dermatology Times, we look around and feel so grateful for all of you who put your trust in us every day! If it weren't for you, there wouldn't be an "us". Happy Thanksgiving from us to you!
5 great books for holiday ‘you time’
November 13th 2017The holidays offer some time to unwind and recalibrate before the calendar flips to the new year. If you enjoy reading, here are five recommendations we hope will resonate with you, inspire you, and maybe move you into the New Year with just a little more insight and enthusiasm.
Revised melanoma staging criteria
November 4th 2017Staging system is derived from a new dataset of patients from 10 cancer centers around the world. Dermatologists should consider AJCC tumor characteristics as well as other factors in risk assessment, counseling, and follow-up plans for patients. Update takes effect in January 2018.
Repurposed antifungal exhibits promising results
November 2nd 2017A novel oral formulation of itraconazole designed to improve bioavailability is leveraging its activity as a Hedgehog pathway inhibitor to provide a low toxicity, effective treatment for patients with BCC Nevus Syndrome. Data show potential for rapid therapeutic benefit.
Venture capital and the future of dermatology: A reassessment
November 1st 2017Dr. Norman Levine offers bits of advice for those considering this type of change in your practice for those considering selling their practices to venture capital-backed enterprises based on his experience with one such company.
Creative marketing or deceptive advertising?
November 1st 2017Dr. Ad employs a variety of advertising methods to grow his practice. Two years ago, he ran an ad that said prolonged use of his $1,000/tube facial cream would negate a need for a facelift. Now he is facing a complaint by a patient who bought 20 tubes and saw no improvement over the course of a year. Dr. Ad claims that his marketing was harmless and no different than most other ads. Is he in trouble?